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Along with chemotherapy and surgery, radiotherapy remains as an important modality in tumor treatment, as it is used to treat approximately 50% of all patients with localized cancer [1-3]. 
However, the use of radiotherapy inevitably leads to exposing the or-
gans/tissues that are entirely or partially excluded from the treatment 
volume [4]. Therefore, out-of-field regions receive dose values due to 
secondary radiation sources, including scattered radiation from col-
limators and beam modifiers, photon leakage through the treatment 
head of the linear accelerator (Linac), and internal patient radiation 
scattering [5]. In a study by Kase, et al. [6], it was found that the ra-
diation scattering from patient is the main cause of dose near the edge 
of treatment field, while the leakage radiation has the main contribu-
tion at large distances from the edge of treatment field. Although dose 
value in out-of-field region is smaller than that in-field region, these 
doses can induce secondary malignancies with a long-latency peri-
od (particularly in radiosensitive tissue/organs) [7-8]. Furthermore, 
knowledge of the peripheral dose can be of very interest when con-
sidering radiation therapy for patients with pregnancy or patients with 
cardiac pacemaker. Therefore, accurate measurement of the peripher-
al dose to normal tissue outside the target volume is essential, to have 
an adequate clinical decision for patients with implanted electronic 
devices or pregnant patients as well as more accurate estimation of the 
radiation-induced secondary cancer risk. 
Generally, it has been accepted that the dose calculation accuracy 
in out-of-field regions by treatment planning systems (TPSs) is poor. 
This can be found out by reviewing the specified protocols for quality 
assurance and commissioning of TPSs, which suggest an agreement 
criterion of up to 50% in the low dose/small dose gradient region of 
photon beams between the TPS calculations and experimental mea-
surements [9-10]. There are several factors which can affect poor per-
formance of TPSs in out-of-field regions, including the lack of TPS 
commissioning for out-of-field regions, the limitations of TPSs in 
modelling the dose contributions from contaminated electrons origi-
nated from the collimator assembly, flattening filter, and secondary 
scattered photons from the Linac’s head [11-12]. 
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There are several studies which have quantified the dose calculation accuracy of different 
TPSs in out-of-field regions [5, 12-16]. In a study, Huang, et al. [5] reported that Pinnacle TPS 
underestimates the out of field dose by an average of 50% for intensity modulated radiation 
therapy (IMRT) treatment plans and this underestimation is worsened with increasing distance 
from the edge of treatment field. Howell, et al. [12] stated that Eclipse TPS underestimated 
out of field doses by an average of 40%. Bahreyni Toossi, et al. [13] revealed that TiGRT TPS 
generally underestimated out-of-field dose by an average of 39% and this underestimation 
increased for areas which are relatively close to the edge of treatment field. In another study, 
Bahreyni Toossi [14] investigated dose accuracy of TiGRT TPS for head and neck region and 
revealed it for most of the points, the difference between calculated and measured dose for out-
of-field regions are less than 40%. Morever, their findings demonstrated TPS underestimated 
dose of the outside field which is mentioned compared to the corresponding measurements. 
Farhood, et al. [15] reported that TiGRT TPS underestimated the out-of-field dose for most 
points in physical wedged field and the confidence limit value for region was 55.24. 
Consequently, underestimation of the dose was received by a radiosensitive organ using a 
TPS, so it leads to increase the probability of contracting another cancer to an underestimation 
of the risk of induction of second cancer. As it was stated by Kry, et al. [17], a 50% variation 
in low dose value can enough so as to cause a remarkable difference in the second cancer risk. 
On the other hand, a severe underestimation of out-of-field dose can lead to a poor clinical 
decision-making for patients with implantable electronic devices or pregnant patients. There-
fore Thus, an assessment of dose at out-of-field regions should not generally rely on TPS cal-
culations. It menas for accurate evaluation of out-of-field dose values other dose reconstruction 
methods should be utilized to reveal accurate evaluation of it. These methods can include cal-
culations by Monte Carlo simulations or other analytical models, measurements in a phantom, 
or other calculation methods [18].
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